General Information of the Drug (ID: M6APDG03108)
Name
Azepan-(2Z)-ylideneamine
Synonyms
Azepan-(2Z)-ylideneamine; 3,4,5,6-tetrahydro-2H-azepin-7-amine; CHEMBL315857; 2214-67-7; iminohomopiperidine; 2-Iminohexahydro-1H-azepine; SCHEMBL1575752; MolPort-007-996-393; GTLJSJNKRLFVSJ-UHFFFAOYSA-N; STL163828; ZINC13746433; BBL012958; BDBM50049257; AKOS002684184; AKOS006375172; MCULE-7781415779
    Click to Show/Hide
Status
Investigative
Structure
Formula
C6H12N2
InChI
1S/C6H12N2/c7-6-4-2-1-3-5-8-6/h1-5H2,(H2,7,8)
InChIKey
GTLJSJNKRLFVSJ-UHFFFAOYSA-N
PubChem CID
9793728
TTD Drug ID
D08ALG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Nitric oxide synthase endothelial (NOS3)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Nitric oxide synthase endothelial (NOS3) is a therapeutic target for Azepan-(2Z)-ylideneamine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Azepan-(2Z)-ylideneamine through regulating the expression of Nitric oxide synthase endothelial (NOS3). [1], [2]
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. doi: 10.1021/jm950766n.